Literature DB >> 35731374

LncRNA-UC.25 + shRNA Alleviates P2Y14 Receptor-Mediated Diabetic Neuropathic Pain via STAT1.

Baoguo Wu1, Congfa Zhou2, Zehao Xiao3, Gan Tang3, Hongmin Guo1, Zihui Hu1, Qixing Hu1, Hao Peng4, Lingzhi Pi4, Zhihua Zhang3, Miaomiao Wang3, Taotao Peng4, Jiaqi Huang3, Shangdong Liang1, Guilin Li5.   

Abstract

Diabetic neuropathic pain (DNP) is a common complication of diabetes, and its complicated pathogenesis, as well as clinical manifestations, has brought great trouble to clinical treatment. The spinal cord is an important part of regulating the occurrence and development of DNP. Spinal microglia can regulate the activity of spinal cord neurons and have a regulatory effect on chronic pain. P2Y12 receptor is involved in DNP. P2Y14 and P2Y12 receptors belong to the Gi subtype of P2Y receptors, but there is no report that the P2Y14 receptor is involved in DNP. Closely related to many human diseases, the dysregulation of long noncoding RNA (lncRNA) has the effect of promoting or inhibiting the occurrence and development of diseases. The aim of this research is to investigate the function of the spinal cord P2Y14 receptor in type 2 DNP and to understand the function as well as the possible mechanism of lncRNA-UC.25 + (UC.25 +) in rat spinal cord P2Y14 receptor-mediated DNP. Our results showed that P2Y14 shRNA can reduce the expression of P2Y14 in DNP rats, thereby restraining the activation of microglia, decreasing the expression of inflammatory factors and the level of p38 mitogen-activated protein kinase (p38 MAPK) phosphorylation. At the same time, UC.25 + shRNA can downregulate the expression of the P2Y14 receptor, reduce the release of inflammatory factors, and diminish the p38 MAPK phosphorylation, indicating that UC.25 + can alleviate spinal cord P2Y14 receptor-mediated DNP. The RNA immunoprecipitation result showed that UC.25 + enriched signal transducers and activators of transcription1 (STAT1) and positively regulated its expression. The chromatin immunoprecipitation result indicated that STAT1 combined with the promoter region of the P2Y14 receptor and positively regulated the expression of the P2Y14 receptor. Therefore, we infer that UC.25 + may alleviate DNP in rats by regulating the expression of the P2Y14 receptor in spinal microglia via STAT1.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Diabetic neuropathic pain; Microglia; P2Y14 receptor; Spinal cord; lncRNA

Mesh:

Substances:

Year:  2022        PMID: 35731374     DOI: 10.1007/s12035-022-02925-0

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.682


  23 in total

1.  Multiple P2Y subtypes in spinal microglia are involved in neuropathic pain after peripheral nerve injury.

Authors:  Kimiko Kobayashi; Hiroki Yamanaka; Fujio Yanamoto; Masamichi Okubo; Koichi Noguchi
Journal:  Glia       Date:  2012-06-26       Impact factor: 7.452

2.  The identification and characterization of novel transcripts from RNA-seq data.

Authors:  Tyler Weirick; Giuseppe Militello; Raphael Müller; David John; Stefanie Dimmeler; Shizuka Uchida
Journal:  Brief Bioinform       Date:  2015-08-17       Impact factor: 11.622

Review 3.  Tramadol for neuropathic pain in adults.

Authors:  Rudolf Martin Duehmke; Sheena Derry; Philip J Wiffen; Rae F Bell; Dominic Aldington; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2017-06-15

Review 4.  Activated microglia in the spinal cord underlies diabetic neuropathic pain.

Authors:  Dongmei Wang; Réjean Couture; Yanguo Hong
Journal:  Eur J Pharmacol       Date:  2014-02-06       Impact factor: 4.432

Review 5.  Glia and pain: is chronic pain a gliopathy?

Authors:  Ru-Rong Ji; Temugin Berta; Maiken Nedergaard
Journal:  Pain       Date:  2013-06-20       Impact factor: 6.961

6.  Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition.

Authors:  Pouya Saeedi; Inga Petersohn; Paraskevi Salpea; Belma Malanda; Suvi Karuranga; Nigel Unwin; Stephen Colagiuri; Leonor Guariguata; Ayesha A Motala; Katherine Ogurtsova; Jonathan E Shaw; Dominic Bright; Rhys Williams
Journal:  Diabetes Res Clin Pract       Date:  2019-09-10       Impact factor: 5.602

Review 7.  Pathophysiology of astroglial purinergic signalling.

Authors:  Heike Franke; Alexei Verkhratsky; Geoffrey Burnstock; Peter Illes
Journal:  Purinergic Signal       Date:  2012-05-01       Impact factor: 3.765

Review 8.  Neuron-microglia interaction by purinergic signaling in neuropathic pain following neurodegeneration.

Authors:  Makoto Tsuda; Kazuhide Inoue
Journal:  Neuropharmacology       Date:  2015-08-29       Impact factor: 5.250

Review 9.  Evolving Insights into the Pathophysiology of Diabetic Neuropathy: Implications of Malfunctioning Glia and Discovery of Novel Therapeutic Targets.

Authors:  Md Habibur Rahman; Mithilesh Kumar Jha; Kyoungho Suk
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

10.  Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study.

Authors:  Yongze Li; Di Teng; Xiaoguang Shi; Guijun Qin; Yingfen Qin; Huibiao Quan; Bingyin Shi; Hui Sun; Jianming Ba; Bing Chen; Jianling Du; Lanjie He; Xiaoyang Lai; Yanbo Li; Haiyi Chi; Eryuan Liao; Chao Liu; Libin Liu; Xulei Tang; Nanwei Tong; Guixia Wang; Jin-An Zhang; Youmin Wang; Yuanming Xue; Li Yan; Jing Yang; Lihui Yang; Yongli Yao; Zhen Ye; Qiao Zhang; Lihui Zhang; Jun Zhu; Mei Zhu; Guang Ning; Yiming Mu; Jiajun Zhao; Weiping Teng; Zhongyan Shan
Journal:  BMJ       Date:  2020-04-28
View more
  1 in total

1.  Editorial: Application of plant secondary metabolites to pain neuromodulation, volume II.

Authors:  Rajeev K Singla; Adriana Gibara Guimarães; Gokhan Zengin
Journal:  Front Pharmacol       Date:  2022-09-26       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.